Clinical Pharmacy Articles

There is an increasing fear that some common infections may soon be untreatable if the causative organisms acquire resistance to all available antibiotics. Most scientists agree that excessive consumption of antibiotics promotes development of resistance among the microbes that cause infectious diseases. Yet information o­n consumption of antibiotics across Europe is not freely available. The European Surveillance o­n Antimicrobial Consumption (ESAC), funded by the European Commission (2001/SID/136), is an international network of surveillance systems, aiming to collect comparable and reliable antibiotic use data in Europe. Based at the University of Antwerp, the project started in November 2001.

For full article Click Here

Disease evaluation by imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) is an accurate, reproducible, and easily accessible methodology used in pharmaceutical trials.

For full article Click Here

Companies that leverage new collaborative technologies in the manufacture, packaging, and distribution of clinical trial materials will be best positioned to reduce their time to market.



For full article Click Here

José Biller and Julien Bogousslavsky, Eds.

For full article Click Here

Background: Among the various markers of myocardial injury, CK-MB subforms MB2, MB1 and their ratio (CKMBS) have been reported to be the most sensitive early marker of acute myocardial infarction. Hypothesis: The aim of this study was to determine if CKMBS is superior to troponin I in the prediction of major cardiac events in patients with acute coronary syndromes. Methods: The prognostic values of CKMBS and troponin I were compared in 100 consecutive patients with acute coronary syndromes. CKMBS and troponin I were measured o­n arrival to the emergency room and if the duration of chest pain was < 8 hours, a second measurement was done 8 hours later. In addition, CK-MB was measured every 8 hours for 24 hours.



For full article Click Here

Many stakeholders have already commented o­n the EU’s incentives for pediatric drug development.

For full article Click Here

Pharmaceutical Representative, Jan 1, 2002

Hospital Pharmacist Vol 7 No 2 p37-41
February 2000

FDA encourages clinical data e-submission and boosting development of new therapies to combat bioterrorism, cancer, and obesity.

For full articale Click Here

All Rights Reserved Although attempts to develop methods for the in vitro cultivation of microsporidia began as early as 1937, the interest in the culture of these organisms was confined mostly to microsporidia that infect insects. The successful cultivation in 1969 of Encephalitozoon cuniculi, a microsporidium of mammalian origin, and the subsequent identification of these organisms as agents of human disease heightened interest in the cultivation of microsporidia. I describe the methodology as well as the cell lines, the culture media, and culture conditions used in the in vitro culture of microsporidia such as Brachiola (Nosema) algerae, Encephalitozoon cuniculi, E. hellem, E. intestinalis, Enterocytozoon bieneusi, Trachipleistophora hominis, and Vittaforma corneae that cause human disease.


For full article Click Here